Ciba Vision Corp.
Division of Novartis AG
Latest From Ciba Vision Corp.
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
The $1.2 billion acquisition of Sauflon Pharmaceuticals will increase Cooper’s penetration in the high-growth daily disposable silicone hydrogel contact lens market.
With a bulging pipeline, piles of cash, and Big Pharma partners knocking on its doors, Isis believes it is under no pressure to sell its own products. But several factors – including outside pressures and issues intrinsic to Isis’ platform model – are coming into play that may hasten its evolution into an integrated biopharma. And for the first time, Isis management appears open to the possibility.
The start of 2013 has seen a flurry of high-level personnel moves. The shake-ups in AstraZeneca will see exits of its R&D president and EVP for commercial, and Astellas will reorganize global management.
- Medical Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Michael Kehoe, CEO
John McKenna, CFO
Manohar Raheja, PhD, Global Head, R&D & Eng.
- Contact Info
Ciba Vision Corp.
Phone: (678) 415-3937
11460 Johns Creek Pkwy.
P.O. Box 105069 Duluth, GA 30097
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.